COVID -19 (SARS-CoV-2) RT-PCR Test

BAYLOR GENETICS

DEMOGRAPHIC INFORMATION

PATIENT

NAME:	Shamuck Riengxay
DATE OF BIRTH:	12/06/1999
AGE:	21
SEX:	M
ETHNICITY:	Not Hispanic or Latino
RACE:	Asian

TEST INFORMATION

TEST CODE:	1299
SAMPLE TYPE:	Nasal Swab in VTM/UTM
COLLECTED ON:	02/04/2021 17:50 CST
RECEIVED ON:	02/05/2021 10:36 CST
REPORTED ON:	02/05/2021 16:04 CST

ADDRESS:	3690 West Lakeshore Drive BATON ROUGE Louisiana 70808
PHONE:	3188806168
MEDICAL RECORD #:	894371137
ACCESSION #:	CE94846
LAB #:	693097
FAMILY #:	1052580

RECIPIENT

PHYSICIAN NAME:	Nathan Shane French
FACILITY:	LSUB
ADDRESS:	Baton Rougue LA 70803
PHONE:	- -
FAX:	- -
EMAIL:	

INDICATIONS:	Asymptomatic
DATE OF SYMPTOM ONSET:	
PRE-EXISTING CONDITIONS:	
DIAGNOSIS CODES:	

RESULT SUMMARY

POSITIVE

SUMMARY

SARS-CoV-2 viral RNA was detected in the submitted specimen.

COMPONENT	RESULT	NOTE	REFERENCE RANGE
SARS-CoV-2 RNA	Positive	Abnormal	Negative

INTERPRETATION

A "Positive" test result indicates that viral RNA from SARS-CoV-2 was detected in the specimen, and the patient is therefore presumed to be infected with the virus and presumed to be contagious. A positive result does not rule out bacterial co-infection or co-infection with other viruses or microorganisms. Laboratory test results should always be considered in the context of clinical findings and epidemiological data in making a final diagnosis and for patient management decisions. Healthcare providers and facilities should follow the reporting guidelines according to their appropriate public health authorities.

TEST DETAILS

This test is a real-time RT-PCR assay intended for the qualitative detection of SARS-CoV-2 viral RNA in respiratory specimens collected from individuals who meet appropriate COVID-19 clinical and/or epidemiological criteria. This test is authorized for in vitro diagnostic use under the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity tests. This test has not been approved or cleared by the FDA. In compliance with this authorization, please visit https://www.baylorgenetics.com for more information and to access the applicable fact sheets for healthcare providers and patients.

The limit of detection for this assay was determined by the manufacturer to be 8.00E-01 genomic RNA copies/µL. This test has been designed to minimize the likelihood of false positive results. False negative, false positive, and indeterminate results may be due to a variety of factors including, but not limited to, improper collection materials and/or technique, improper storage and/or shipping conditions, specimen contamination, specimen degradation, presence of interfering or inhibiting substances, cross-reactivity with other agents, presence of sequence variants in the viral targets of the assay, and other factors. Repeat testing should be considered when deemed appropriate. In the case of repeat testing, strict attention to specimen collection protocols and transport conditions should be utilized.

ELECTRONICALLY SIGNED BY

Christine M. Eng, M.D.
Medical Director

Brian Y. Merritt, M.D.
Medical Director

2450 Holcombe Blvd.
Grand Blvd. Receiving Dock
Houston, TX 77021-2024
T 1.800.411.4363
F 1.800.434.9850
baylorgenetics.com